Hillevax, Inc. (HLVX)
$14.03
+0.19
(+1.37%)▲
Insights on Hillevax, Inc.
Vs SGEN
In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 104.2%
Performance
- $13.71$14.10$14.03
2.28%
Downside
Day's Volatility :2.76%
Upside
0.5%
- $9.94$22.21$14.03
29.15%
Downside
52 Weeks Volatility :55.25%
Upside
36.83%
Returns
| Period | Hillevax, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 9.58% | -2.6% | 0.0% |
6 Months | -16.27% | 2.2% | 0.0% |
1 Year | -27.27% | -4.3% | -3.4% |
3 Years | -27.5% | 19.1% | -4.7% |
Highlights
Market Capitalization | 667.9M |
Book Value | $6.56 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.29 |
Wall Street Target Price | 28.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -21.07% |
Return On Equity TTM | -36.8% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -115.7M |
Diluted Eps TTM | -2.29 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.08 |
EPS Estimate Next Year | -3.21 |
EPS Estimate Current Quarter | -0.84 |
EPS Estimate Next Quarter | -1.06 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 101.35%
Technicals Summary
Sell
Neutral
Buy
Hillevax, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Hillevax, Inc. | 29.35% | -16.27% | -27.27% | -27.5% | -27.5% |
 Moderna, Inc. | 4.93% | -38.23% | -55.68% | -49.12% | 317.85% |
 Regeneron Pharmaceuticals, Inc. | 2.62% | 9.54% | 7.63% | 54.66% | 119.47% |
 Novo Nordisk A/s | 7.75% | 29.99% | 71.36% | 209.46% | 351.9% |
 Seagen, Inc. | 0.13% | 10.52% | 76.89% | 25.9% | 249.5% |
 Vertex Pharmaceuticals Incorporated | -2.03% | 7.65% | 11.07% | 53.76% | 96.32% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Hillevax, Inc. | NA | NA | NA | -3.08 | -0.37 | -0.21 | 0.0 | 6.56 |
Moderna, Inc. | 24.73 | NA | 0.0 | -12.11 | -0.22 | -0.07 | 0.0 | 35.32 |
Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.51 | 0.17 | 0.09 | 0.01 | 234.47 |
Novo Nordisk A/s | 41.76 | 41.76 | 2.03 | 2.65 | 0.89 | 0.22 | 0.01 | 20.77 |
Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
Vertex Pharmaceuticals Incorporated | 26.68 | 26.68 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Hillevax, Inc. | Buy | $667.9M | -27.5% | NA | 0.0% |
Moderna, Inc. | Buy | $29.8B | 317.85% | 24.73 | -38.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 119.47% | 22.78 | 30.47% |
Novo Nordisk A/s | Buy | $458.4B | 351.9% | 41.76 | 35.11% |
Seagen, Inc. | Hold | $40.0B | 249.5% | NA | -32.61% |
Vertex Pharmaceuticals Incorporated | Buy | $91.4B | 96.32% | 26.68 | 35.94% |
Institutional Holdings
Deerfield Management Co
6.88%The Carlyle Group Inc
3.80%T. Rowe Price Investment Management,Inc.
2.94%Franklin Resources Inc
2.65%BlackRock Inc
2.62%BRAIDWELL LP
2.58%
Company Information
hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Organization | Hillevax, Inc. |
Employees | 62 |
CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Industry | Services |
